Last Updated: November 16, 2026

Details for Patent: 6,770,675

« Back to Dashboard


Summary for Patent: 6,770,675
Title:Compositions and methods for reducing ocular hypertension
Abstract:An improved ophthalmic composition, including docosanoid active agents, which is especially useful in lowering intraocular pressure associated with glaucoma. Improvements in IOP reduction efficacy, preservative efficacy and reduced additive concentrations are achieved by utilizing the disclosed compositions which include a docosanoid active agent (e.g., isopropyl unoprostone), in conjunction with selected non-ionic surfactants, preservatives, and non-ionic tonicity adjusting agents.
Inventor(s):Kenneth Warren Reed, Shau Fong Yen, Mary Sou, Regina Flinn Peacock
Assignee: R Tech Ueno Ltd
Application Number:US09/812,162
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;
Patent landscape, scope, and claims:

United States Patent 6,770,675: Claim Scope, Expiration, Litigation Risk, and Ophthalmic Formulation Landscape

U.S. Patent No. 6,770,675 covers ophthalmic compositions that combine a docosanoid active agent with two nonionic surfactants at a combined concentration below the amount required for either surfactant alone to solubilize the active agent. It also covers a separate preservative-stabilization method using a docosanoid, polysorbate 80, benzalkonium chloride, mannitol, and optionally EDTA.

The patent is directed primarily to formulation technology rather than the docosanoid molecule itself. Its practical value was strongest for ophthalmic products containing isopropyl unoprostone, particularly formulations designed to balance solubility, ocular tolerability, and preservative effectiveness. The patent’s U.S. term has expired under the ordinary 20-year patent-term framework, so it does not create a current U.S. blocking right. Its claims remain relevant for historical freedom-to-operate analysis, patent-family mapping, and evaluation of later continuation or foreign rights.

What does U.S. Patent 6,770,675 cover?

The patent contains two distinct claim groups:

Claim group Claims Subject matter Principal limitation
Dual-surfactant composition 1-5 Ophthalmic composition containing a docosanoid and two nonionic surfactants Total surfactant concentration must be below the concentration required for either individual surfactant to solubilize the docosanoid
Ocular-hypertension method 6 Administration of the composition to ocular fluids or tissue Same dual-surfactant and sub-solubilizing-concentration limitation
Preservative-enhancement method 7-9 Method for restoring preservative effectiveness in a docosanoid formulation Requires mannitol and a nonionic surfactant that improves solubility but reduces preservative performance

The claims use “comprising,” which is an open-ended transitional term. A formulation containing the claimed components may still fall within the claims if it includes additional excipients, buffers, tonicity agents, chelators, viscosity modifiers, or preservatives.

What is the scope of independent claim 1?

Claim 1 requires four principal elements:

  1. A docosanoid active agent.
  2. A first nonionic surfactant.
  3. A second nonionic surfactant.
  4. An ophthalmically acceptable carrier.

The critical limitation is comparative and functional. The total concentration of both surfactants must be lower than the surfactant concentration that would be required to solubilize the docosanoid when either surfactant is evaluated individually.

This limitation distinguishes the claimed formulation from a conventional micellar formulation in which one surfactant is used at a concentration sufficient by itself to solubilize the active agent. The claim instead targets a synergistic or cooperative surfactant system that improves formulation performance at a lower combined surfactant load.

How the claim’s solubility limitation would be analyzed

A likely infringement or validity analysis would require comparison of:

  • The docosanoid concentration.
  • The identity and concentration of each nonionic surfactant.
  • The combined surfactant concentration.
  • The concentration of the first surfactant required to solubilize the docosanoid when used alone.
  • The concentration of the second surfactant required to solubilize the docosanoid when used alone.
  • The test conditions, including temperature, pH, ionic strength, equilibration time, and analytical method.

The claim does not define “solubilize.” That creates an evidentiary issue. Solubility could be assessed by visual clarity, filtered assay, equilibrium solubility, particle-count testing, or another validated analytical method. The relevant comparison must use consistent conditions for the individual-surfactant controls and the dual-surfactant formulation.

A formulation can satisfy the claim even if the two surfactants together provide substantial solubilization. The claim does not require poor solubility. It requires that the combined amount be below the amount needed for either surfactant alone.

What formulations are protected by claims 2 through 5?

Claims 2 through 5 progressively narrow claim 1.

Claim Added limitation Commercial formulation significance
2 Surfactants selected from polyoxyethylene sorbitan fatty acid esters, polyoxyethylene alkyl ethers, or mixtures Covers broad classes including polysorbates and Brij-type surfactants
3 First surfactant is a polyoxyethylene sorbitan fatty acid ester; second is a polyoxyethylene alkyl ether Requires two different surfactant families
4 First is a Polysorbate compound; second is a Brij compound Narrows the classes to named commercial surfactant families
5 Total nonionic surfactant concentration is about 0.3% to 2.0% by weight Adds a quantitative concentration range

Claim 5 is not a stand-alone claim. It incorporates all limitations of claims 1 through 4 and adds the 0.3% to 2.0% total surfactant range. A formulation outside that range may still infringe claim 4 or claim 1 if the other limitations are met.

The use of “about” gives the concentration limitation some numerical flexibility. The applicable range would depend on prosecution history, specification disclosure, experimental examples, and the extent to which a proposed concentration performs the same claimed function.

What are the likely covered surfactant combinations?

The claim language points to combinations such as:

  • Polysorbate 80 with a Brij surfactant.
  • Another polysorbate with a polyoxyethylene alkyl ether.
  • A mixed polysorbate/Brij system containing a docosanoid.
  • A formulation within approximately 0.3% to 2.0% total surfactant for claim 5.

The claims do not require a particular ratio between the two surfactants. A product with a very small amount of one surfactant and a substantially larger amount of the other could remain within the literal scope if the total concentration and comparative solubility requirement are satisfied.

How broad is the docosanoid limitation?

“Docosanoid” is broader than isopropyl unoprostone. It generally refers to biologically active compounds derived from or structurally related to 22-carbon fatty-acid pathways. The specification and prosecution record would determine the operative construction, but claim 1 is not expressly limited to one active ingredient.

Claim 8 is narrower. It specifically identifies:

  • Isopropyl unoprostone as the docosanoid active agent.
  • Benzalkonium chloride as the strong preservative.
  • Polysorbate 80 as the nonionic surfactant.

This distinction matters commercially. A product using isopropyl unoprostone could be evaluated under both the broad composition claims and the narrower preservative-method claim. A different docosanoid could potentially fall within claims 1 and 6 while avoiding claim 8.

What does claim 6 protect?

Claim 6 covers a method of reducing ocular hypertension by administering to ocular fluids or ocular tissue a composition having the same core features as claim 1.

The claim requires:

  • A docosanoid active agent.
  • Two nonionic surfactants.
  • An ophthalmically acceptable carrier.
  • A total surfactant concentration below the solubilization threshold for either individual surfactant.

The method claim does not specify:

  • Dose.
  • Frequency.
  • Route beyond administration to ocular fluids or tissue.
  • Treatment duration.
  • Patient population.
  • Required reduction in intraocular pressure.
  • Specific formulation volume.
  • Specific pH or preservative.

Because the claim is open-ended and does not prescribe a particular dosage regimen, a broad range of topical ophthalmic administration protocols could potentially satisfy its structural limitations. The principal disputes would likely concern whether the administered product contains two qualifying surfactants and whether the comparative solubility limitation is met.

What does claim 7 protect?

Claim 7 is materially different from claims 1 through 6. It covers a method for increasing the effectiveness of a strong preservative in a solution containing a docosanoid active agent and a nonionic surfactant.

The method requires admixing:

  1. A docosanoid active agent.
  2. A strong preservative.
  3. A nonionic surfactant that increases docosanoid solubility but decreases preservative effectiveness.
  4. Mannitol in an amount sufficient to increase preservative effectiveness.
  5. An ophthalmically acceptable carrier.

Unlike claim 1, claim 7 does not require two nonionic surfactants. It focuses on the interaction among:

  • The active ingredient.
  • The surfactant.
  • The preservative.
  • Mannitol.

Claim 7 therefore addresses a different formulation problem. A company could avoid claims 1 through 6 by using only one surfactant, yet still face claim 7 if its formulation uses the claimed preservative-restoration strategy.

What do claims 8 and 9 add?

Claim 8 specifies the principal formulation combination:

  • Isopropyl unoprostone.
  • Benzalkonium chloride.
  • Polysorbate 80.
  • Mannitol.
  • Ophthalmically acceptable carrier.

Claim 9 adds EDTA to the method of claim 7. EDTA, commonly used as a chelating agent, can affect preservative performance by binding metal ions and altering microbial susceptibility or preservative interactions.

Claim 9 is narrower than claim 7 but may be easier to test analytically because the component list is more specific.

When did U.S. Patent 6,770,675 lose exclusivity?

U.S. Patent 6,770,675 issued on August 3, 2004. Its enforceable U.S. term expired under the standard 20-year term calculated from the relevant nonprovisional filing date. The patent is therefore expired and does not present a current U.S. patent-enforcement barrier.

Event Date or status
Patent issued August 3, 2004
Patent term basis 20 years from the applicable earliest nonprovisional filing date
Current U.S. status Expired
Current blocking value No enforceable U.S. exclusivity from this patent
Historical relevance Formulation, Orange Book, litigation, and family analysis

Patent-term adjustment, patent-term extension, terminal disclaimers, and priority-chain details can affect the exact expiration date. Those mechanisms do not change the present conclusion that the patent is no longer enforceable in the United States.

The expiration of this patent does not establish that all related patents have expired. Continuations, divisionals, foreign counterparts, or separate active-ingredient patents must be assessed independently.

What is the Orange Book status of the patent?

The patent is not a current source of Orange Book exclusivity. Orange Book relevance depends on whether the patent was listed against an approved drug product and whether the listing remained active during the product’s commercial life.

For an isopropyl-unoprostone product, the relevant regulatory history includes Rescula, an ophthalmic product associated with isopropyl unoprostone. FDA approval history, product discontinuation status, and Orange Book listing history must be separated:

  • FDA approval does not prove that a particular patent was listed.
  • A patent listing does not prove that the patent remains enforceable.
  • A discontinued product can remain in FDA historical databases without creating current market exclusivity.
  • Patent expiration removes the patent-based barrier even if the product’s historical listing remains visible in archived records.

The FDA Orange Book should be reviewed for historical patent-listing data, while FDA Drugs@FDA should be used for approval and marketing-status records.[2,3]

Were Paragraph IV challenges likely under this patent?

A Paragraph IV certification would be relevant only if the patent was listed in the Orange Book against the reference listed drug and remained unexpired when an ANDA was submitted.

For a formulation patent of this type, an ANDA applicant could potentially argue that:

  • The proposed product uses only one nonionic surfactant.
  • The surfactant combination does not meet the comparative solubility limitation.
  • The total surfactant concentration falls outside the claimed range.
  • The active ingredient is not a claimed docosanoid.
  • The formulation does not use mannitol in an amount sufficient to increase preservative effectiveness.
  • The preservative is not a claimed strong preservative.
  • The product does not contain the specific isopropyl-unoprostone/polysorbate-80/benzalkonium-chloride combination.
  • The patent is expired or invalid.

No current Paragraph IV risk arises from an expired patent. Historical ANDA litigation would require a docket-specific review of the relevant product, patent listing, and filing date. The patent number alone does not establish that a Paragraph IV certification or 30-month stay occurred.

What patent litigation affects U.S. Patent 6,770,675?

The patent’s present litigation risk is zero because an expired U.S. patent cannot support a new infringement action for post-expiration conduct. Historical litigation risk is a separate question.

A complete litigation review should distinguish:

Issue Relevance
Infringement complaint filed before expiration Could have preserved claims for damages for the pre-expiration period
ANDA litigation Could have delayed generic approval under the Hatch-Waxman framework
Declaratory judgment Could have tested validity or noninfringement
Settlement agreement Could have affected launch timing without deciding validity
Patent expiration Ends prospective infringement exposure
Related patent family May preserve separate rights after this patent expired

The supplied claims do not identify a litigation history, settlement agreement, or license. The patent itself does not establish that any settlement or license existed.

How strong was the patent estate?

The patent was technically focused and commercially strongest against a formulation that used the specified excipient architecture. Its strengths and weaknesses can be summarized as follows:

Factor Assessment
Claim breadth Moderate for docosanoid formulations; narrower for named surfactant combinations
Composition protection Meaningful because claim 1 combines structural and functional limitations
Method protection Moderate; claims 6 and 7 target use and preservative performance
Design-around exposure Material, because competitors could alter surfactant identity, concentration, preservative, or mannitol use
Proof burden Significant for the comparative solubility and preservative-effectiveness limitations
Active-ingredient coverage Limited; the patent is not a broad molecule patent
Current enforceability None in the United States because the patent is expired
Biosimilar relevance None; isopropyl unoprostone is a small molecule, not a biologic

The functional solubility limitation can make claim 1 difficult to invalidate for lack of written description if the specification provides representative examples across the claimed genus. It can also make infringement more fact-intensive because the parties must agree on test conditions and analytical endpoints.

At the same time, functional language can create enablement, indefiniteness, and proof-of-infringement issues. The scope is less predictable than a claim limited to fixed percentages and named excipients.

What generic launch scenarios existed?

For a generic or alternative ophthalmic product, the principal launch routes would have included:

Formulation design-around

A competitor could use:

  • A single nonionic surfactant.
  • An ionic or amphoteric surfactant.
  • A different solubilization technology.
  • A different preservative system.
  • A surfactant concentration outside the claim 5 range.
  • A formulation that does not depend on mannitol to restore preservative effectiveness.

Paragraph IV certification

If the patent was listed and unexpired at the time of ANDA filing, an applicant could certify that the patent was invalid, unenforceable, or not infringed. Claim 1’s comparative solubility requirement would have been a central noninfringement issue.

Paragraph III certification

After patent expiration, an applicant could certify that it would not market until the listed patent expired. That barrier no longer applies to this patent.

505(b)(2) pathway

A product with a different formulation, delivery system, or clinical-use profile could potentially use the 505(b)(2) pathway, subject to FDA requirements and any remaining listed patents or exclusivities associated with the reference product.

How does this patent compare with molecule, method-of-use, and manufacturing patents?

Patent category Typical protection Relationship to U.S. 6,770,675
Active-ingredient patent Chemical structure, stereochemistry, salts, esters Separate from the formulation claims
Formulation patent Excipients, concentrations, stability, solubility Directly aligned with 6,770,675
Method-of-use patent Ocular hypertension or glaucoma treatment Claim 6 has this character but is tied to the composition
Manufacturing patent Synthesis, purification, crystallization, sterile filling Not addressed by the supplied claims
Device or delivery patent Containers, inserts, pumps, sustained-release systems Not addressed
Regulatory exclusivity New chemical entity, new clinical investigation, orphan exclusivity Separate from patent rights

The patent does not cover manufacture of isopropyl unoprostone, filling operations, container systems, or generic ophthalmic products that do not practice the claimed formulation or method.

What geographic coverage exists?

U.S. Patent 6,770,675 provides protection only in the United States. Foreign equivalents must be evaluated separately by jurisdiction.

Relevant geographic questions include:

  • Whether a PCT application was filed.
  • Which national-phase applications entered Europe, Canada, Japan, Australia, or other markets.
  • Whether foreign patents expired on the same schedule.
  • Whether supplementary protection certificates or patent-term extensions existed.
  • Whether foreign claims were limited to isopropyl unoprostone or covered broader docosanoid formulations.

U.S. expiration does not terminate foreign rights. Conversely, foreign patent rights do not create U.S. infringement exposure.

What manufacturing and intellectual-property barriers remain?

The patent does not create a current U.S. manufacturing barrier. Remaining barriers may include:

  • Know-how for maintaining clarity and physical stability.
  • Sterile ophthalmic manufacturing controls.
  • Preservative compatibility.
  • Container-closure adsorption or leachables.
  • Active-agent degradation.
  • Scale-up of surfactant blending.
  • FDA requirements for ophthalmic sterility, particulate control, and preservative effectiveness.
  • Separate patents covering the active ingredient, process, container, or delivery device.

For a generic developer, the most important technical work would be confirming that the selected surfactant system does not trigger claim 1 or claim 6 in jurisdictions where a corresponding patent remains active, and that the preservative system does not reproduce the claim 7 architecture.

Key Takeaways

  • U.S. Patent 6,770,675 is a formulation patent centered on docosanoid ophthalmic compositions.
  • Claims 1 through 6 require two nonionic surfactants and a combined concentration below the individual-surfactant solubilization threshold.
  • Claims 2 through 5 narrow the technology toward polysorbate and Brij combinations, with claim 5 specifying approximately 0.3% to 2.0% total surfactant.
  • Claim 7 is a separate preservative-enhancement method using mannitol to counteract surfactant-related loss of preservative effectiveness.
  • Claim 8 specifically targets isopropyl unoprostone, benzalkonium chloride, and polysorbate 80.
  • Claim 9 adds EDTA.
  • The U.S. patent has expired and creates no current U.S. blocking right.
  • The patent is not relevant to biosimilar competition because isopropyl unoprostone is a small molecule.
  • Any remaining commercial risk must come from separate active-ingredient, formulation, manufacturing, device, foreign, or regulatory rights.
  • The most important technical claim issue is the comparative solubility test required by claim 1.

FAQs

Does U.S. Patent 6,770,675 cover all ophthalmic formulations containing unoprostone?

No. It covers formulations that satisfy the specific docosanoid, nonionic-surfactant, carrier, and comparative solubility limitations. Claim 8 is narrower and requires isopropyl unoprostone, benzalkonium chloride, polysorbate 80, mannitol, and the required ophthalmic formulation context.

Can a formulation avoid the patent by using polysorbate 80 alone?

A formulation using only polysorbate 80 would generally not meet the two-surfactant requirement of claims 1 through 6. It could still require analysis under claim 7 if it uses a docosanoid, strong preservative, mannitol, and the claimed preservative-effectiveness mechanism.

Does claim 5 cover every formulation containing 0.3% to 2.0% surfactant?

No. Claim 5 incorporates all limitations of claims 1 through 4. The formulation must also contain the claimed docosanoid, polysorbate/Brij-type surfactants, ophthalmically acceptable carrier, and comparative solubility relationship.

Is mannitol required in the dual-surfactant composition claims?

No. Mannitol is required by claim 7 and its dependent claims. Claims 1 through 6 do not expressly require mannitol.

Does patent expiration eliminate FDA approval requirements for a generic ophthalmic product?

No. Patent expiration removes the patent barrier but does not eliminate FDA requirements for an ANDA, 505(b)(2) application, sterility, quality, bioequivalence, manufacturing controls, or labeling.

References

  1. United States Patent No. 6,770,675. (2004). Ophthalmic compositions comprising docosanoids and non-ionic surfactants. United States Patent and Trademark Office.

  2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

  3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

  4. United States Code, 35 U.S.C. § 154. (2024). Contents and term of patent; provisional rights. Cornell Law School Legal Information Institute. https://www.law.cornell.edu/uscode/text/35/154

  5. United States Code, 21 U.S.C. § 355. (2024). New drugs. Cornell Law School Legal Information Institute. https://www.law.cornell.edu/uscode/text/21/355

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 6,770,675

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.